Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.
- and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.
- Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches.
- At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations.
- “Cole’s broad commercial knowledge and leadership experience will be invaluable in helping Cogent expand from a research and development company to a fully-integrated commercial organization.”
“I have been impressed with Cogent’s rapid progress developing bezuclastinib in multiple patient populations,” said Mr. Pinnow.